Study shows that treatment with GSK864 as IDH1 inhibitor binding an allosteric site on IDH1 reduces the NADPH/NADP+ ratio and prolongs the survival of glioblastoma multiforme (GBM) PDXs model.125 AGI-6780 treatment, binding with IDH2 or mutant IDH2 in an allosteric manner at the dimer interface, reduce the IDH2 activity and lead to the repression of cell growth in lung cancer.134 Mutant IDH-targeted therapy and a number of important recent pre-clinical and clinical studies in IDH-mutant solid tumors have been extensively reviewed elsewhere,147 and listed in Table 2. Here, IDH2 is linked to lung cancer.